View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
October 8, 2012

Novavax begins phase two dose-ranging RSV vaccine trial

Clinical-stage biopharmaceutical company Novavax has begun enrolment in the phase two dose-ranging trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age.

RSV

Clinical-stage biopharmaceutical company Novavax has begun enrolment in the phase two dose-ranging trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age.

The randomised, blinded, placebo-controlled study is designed to evaluate the immunogenicity and safety of two dose levels of Novavax’s RSV-F protein nanoparticle vaccine, with and without aluminum phosphate as an adjuvant.

Novavax senior vice president and chief medical officer Gregory Glenn said the study will determine the optimal dosing regimen for future studies and the potential adjuvant effect of aluminum phosphate besides the evaluation of the safety and immunogenicity of RSV vaccine candidate in an important patient population.

"Previous clinical and preclinical findings have suggested that immunization with our nanoparticle vaccine produces functional neutralizing antibodies to multiple sites on the F protein," Glenn added.

"We expect to report top-line results from this trial, through day 56 observations, in the first quarter of 2013."

The study is being conducted in collaboration with PATH, an international nonprofit organisation that will fund approximately $2m to support the trial.

Around 330 women of childbearing age are expected to be enrolled in the study and will receive either one or two intramuscular injections at each dose level of vaccine or placebo at days 0 and 28.

According to the study design, the safety and immunogenicity will be evaluated over six and four month periods, respectively.


Image: The electron micrograph of the Respiratory Syncytial Virus (RSV) pathogen. Credit: CDC/ Dr. Erskine Palmer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena